Search research articles
Contact Us
Filters
Showing results (191-200 of 240) with videos related to
Page
of 24
Sort By:
F1000Research
|
August 11, 2017
MinION Analysis and Reference Consortium: Phase 2 data release and analysis of R9.0 chemistry
Miten Jain, John R Tyson, Matthew Loose, et al.
Journal of Medicinal Chemistry
|
August 5, 2016
Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening
Paul Czodrowski, Aurélie Mallinger, Dirk Wienke, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 21, 2007
Plexin-B1 mutations in prostate cancer
Oscar Gee-Wan Wong, Tharani Nitkunan, Izumi Oinuma, et al.
Leukemia
|
February 23, 2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A S Moore, A Faisal, D Gonzalez de Castro, et al.
British Journal of Cancer
|
May 27, 2010
Guidelines for the welfare and use of animals in cancer research
P Workman, E O Aboagye, F Balkwill, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2018
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
Jacqueline H L Fok, Somaieh Hedayat, Lei Zhang, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Journal of Medicinal Chemistry
|
February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)
Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
Aurélie Mallinger, Kai Schiemann, Christian Rink, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 240) with videos related to
Sort By:
Page
of 24
F1000Research
|
August 11, 2017
MinION Analysis and Reference Consortium: Phase 2 data release and analysis of R9.0 chemistry
Miten Jain, John R Tyson, Matthew Loose, et al.
Journal of Medicinal Chemistry
|
August 5, 2016
Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening
Paul Czodrowski, Aurélie Mallinger, Dirk Wienke, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 21, 2007
Plexin-B1 mutations in prostate cancer
Oscar Gee-Wan Wong, Tharani Nitkunan, Izumi Oinuma, et al.
Leukemia
|
February 23, 2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A S Moore, A Faisal, D Gonzalez de Castro, et al.
British Journal of Cancer
|
May 27, 2010
Guidelines for the welfare and use of animals in cancer research
P Workman, E O Aboagye, F Balkwill, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2018
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
Jacqueline H L Fok, Somaieh Hedayat, Lei Zhang, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Journal of Medicinal Chemistry
|
February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)
Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
Aurélie Mallinger, Kai Schiemann, Christian Rink, et al.
Page
of 24